# Understanding Dorsocervical Fat Pad Enlargement with GLP-1 Drugs > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/dorsocervical-fat-pad-enlargement-glp-1-weight-loss-effects/ > **Published:** 2026-04-24T01:44:13-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:13:29-04:00 > **Clinical Summary:** Explore dorsocervical fat pad enlargement as a side effect of GLP-1 weight loss drugs. Learn about causes, patient counseling, and management strategies. --- GLP-1 Clinical Relevance  #43Contextual Information  Background context; limited direct clinical applicability. ⚕ GLP-1 News  |  CED Clinic Clinical GuidanceObservational StudyLipodystrophyGLP-1 Receptor AgonistDermatologyAdults with ObesityAdverse Effect ManagementDorsal Fat Pad RedistributionBuffalo Hump FormationGLP-1 Associated ComplicationsBody Composition ChangesCosmetic Treatment Protocols Why This Matters Family medicine clinicians prescribing GLP-1 receptor agonists need to counsel patients that rapid weight loss from these agents can result in localized adipose tissue redistribution, including dorsocervical fat pad prominence or persistence, which may necessitate discussion of cosmetic interventions and impacts patient satisfaction despite metabolic improvement. Understanding this aesthetic consequence helps clinicians set realistic expectations, distinguish expected physiologic changes from complications, and proactively address patient concerns that might otherwise lead to therapy discontinuation or dissatisfaction. Recognition of this pattern allows for integrated counseling around body composition changes as part of comprehensive GLP-1 management rather than unexpected or unexplained physical changes patients may interpret as adverse effects. Clinical Summary GLP-1 receptor agonist medications have demonstrated significant efficacy in weight loss and metabolic improvement, but clinical experience has identified an emerging phenotype of lipodystrophic changes associated with their use. Clinical guidance published by Prado-Wright documents an increasing number of patient consultations specifically related to dorsocervical fat accumulation, colloquially referred to as buffalo hump or lipohypertrophy in the interscapular region, occurring in the context of GLP-1 therapy. This presentation represents a distinct pattern of regional adiposity redistribution that warrants clinical recognition and appropriate [patient counseling](https://cedclinic.com/stroke-risk-assessment-substance-use/) prior to initiating GLP-1 therapy. The mechanism underlying this phenomenon appears related to selective regional lipid redistribution during weight loss cycles induced by GLP-1 medications. While patients typically achieve substantial overall weight reduction and improvements in glycemic control and cardiovascular risk factors, the preferential sparing or paradoxical accumulation of dorsocervical adipose tissue creates an aesthetic concern that significantly impacts patient satisfaction and treatment adherence. This selective adiposity pattern may reflect differential regional insulin sensitivity, local lipid metabolism alterations, or changes in distribution patterns during rapid weight cycling associated with GLP-1 use. Clinicians prescribing GLP-1 receptor agonists should anticipate discussing potential for regional lipid redistribution with patients during the informed consent process. Awareness of this pattern enables appropriate expectation management and may inform decisions regarding dosing titration strategies or concurrent management approaches. Patients experiencing bothersome dorsocervical lipohypertrophy during GLP-1 therapy may benefit from specialist evaluation to determine whether additional interventions or dose adjustments are warranted, ensuring that overall metabolic benefits of GLP-1 therapy are optimized while addressing cosmetic concerns affecting [quality of life](https://cedclinic.com/cannabis-policy-enforcement-february-26-2026/). Clinical Takeaway Clinical Takeaway Rapid weight loss from GLP-1 medications can result in excess skin and fat redistribution, including dorsocervical fat pad enlargement (buffalo hump appearance), requiring proactive [patient counseling](https://cedclinic.com/stroke-risk-assessment-substance-use/). Patients losing weight quickly may experience visible skin changes that affect body image and psychosocial well-being despite metabolic improvements. Family physicians should discuss realistic body composition changes during GLP-1 therapy initiation and set appropriate expectations about skin elasticity limitations. When counseling patients, frame these changes as a manageable aspect of rapid weight loss rather than a treatment failure, and discuss timing of any cosmetic interventions only after weight stabilization is achieved. Dr. Caplan’s Take “I’ve observed this phenomenon firsthand in my practice, and it warrants serious discussion with patients considering GLP-1 therapy. The dorsal fat pad accumulation we’re seeing appears related to the rapid visceral fat loss these medications produce, leaving some patients with disproportionate upper back fullness that can be psychologically distressing. When counseling patients about GLP-1 treatment, I now explicitly address that while we’re achieving excellent metabolic outcomes and visceral fat reduction, the distribution of remaining subcutaneous fat may shift in ways that aren’t always cosmetically ideal, and that’s a conversation worth having upfront rather than discovering it months into therapy.” Clinical Perspective The emergence of dorsocervical fat accumulation in GLP-1 users represents a paradoxical metabolic consequence that warrants clinical acknowledgment, as rapid visceral fat mobilization and heterogeneous adipose tissue remodeling can precipitate localized lipohypertrophy despite overall weight loss. This phenomenon underscores the need for comprehensive body composition assessment beyond BMI metrics and emphasizes informed consent discussions regarding potential morphologic changes during GLP-1 therapy. Clinicians should incorporate systematic pre-treatment photographic documentation and establish baseline dorsocervical measurements to enable early detection of this complication and facilitate timely interventions, including dose optimization, drug rotation, or referral to appropriate specialists when clinically indicated. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Exert%20BodySculpt%20Addresses%20Rise%20in%20Buffalo%20Hump%20Cases%20Linked%20to%20%3Cb%3EGLP-1%20Weight%20%20%40drcaplan&url=https%3A%2F%2Fmarkets.businessinsider.com%2Fnews%2Fstocks%2Fexert-bodysculpt-addresses-rise-in-buffalo-hump-cases-linked-to-glp-1-weight-loss-drugs-1036053872)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fmarkets.businessinsider.com%2Fnews%2Fstocks%2Fexert-bodysculpt-addresses-rise-in-buffalo-hump-cases-linked-to-glp-1-weight-loss-drugs-1036053872)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Exert%20BodySculpt%20Addresses%20Rise%20in%20Buffalo%20Hump%20Cases%20Linked%20to%20%3Cb%3EGLP-1%20Weight%20%20--%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fmarkets.businessinsider.com%2Fnews%2Fstocks%2Fexert-bodysculpt-addresses-rise-in-buffalo-hump-cases-linked-to-glp-1-weight-loss-drugs-1036053872)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/glp-1-news/feed/) 📰 Source: [https://markets.businessinsider.com/news/stocks/exert-bodysculpt-addresses-rise-in-buffalo-hump-cases-linked-to-glp-1-weight-loss-drugs-1036053872](https://markets.businessinsider.com/news/stocks/exert-bodysculpt-addresses-rise-in-buffalo-hump-cases-linked-to-glp-1-weight-loss-drugs-1036053872) Nationwide GLP-1 Care Looking for thoughtful, physician-led GLP-1 guidance? CED Clinic offers GLP-1 and metabolic guidance across the United States, including evaluation, prescribing support, side-effect management, and longer-term follow-up for people seeking careful, personalized care. [Learn More](https://cedclinic.com/metabolic/) [Book Now](https://book.squareup.com/appointments/kn3vehwoiz6to6/location/DPV0VF8Y74WA7/services) Table of Contents - [FAQ](#FAQ)[What is a buffalo hump and why is it appearing in people taking GLP-1 medications?](#What_is_a_buffalo_hump_and_why_is_it_appearing_in_people_taking_GLP-1_medications) - [If I am losing weight on a GLP-1 medication, why would I develop a buffalo hump?](#If_I_am_losing_weight_on_a_GLP-1_medication_why_would_I_develop_a_buffalo_hump) - [Is a buffalo hump a permanent side effect of GLP-1 therapy?](#Is_a_buffalo_hump_a_permanent_side_effect_of_GLP-1_therapy) - [How common is buffalo hump formation among GLP-1 users?](#How_common_is_buffalo_hump_formation_among_GLP-1_users) - [Can I prevent a buffalo hump while taking GLP-1 medications?](#Can_I_prevent_a_buffalo_hump_while_taking_GLP-1_medications) - [What should I do if I notice a buffalo hump developing during GLP-1 treatment?](#What_should_I_do_if_I_notice_a_buffalo_hump_developing_during_GLP-1_treatment) - [Are there treatments available for buffalo hump that developed from GLP-1 use?](#Are_there_treatments_available_for_buffalo_hump_that_developed_from_GLP-1_use) - [Does stopping my GLP-1 medication eliminate a buffalo hump?](#Does_stopping_my_GLP-1_medication_eliminate_a_buffalo_hump) - [Is a buffalo hump a sign that GLP-1 therapy is not working properly?](#Is_a_buffalo_hump_a_sign_that_GLP-1_therapy_is_not_working_properly) - [Should I be concerned about a buffalo hump if I have not noticed one yet?](#Should_I_be_concerned_about_a_buffalo_hump_if_I_have_not_noticed_one_yet) - [Related](#Related) ## FAQ #### What is a buffalo hump and why is it appearing in people taking GLP-1 medications? A buffalo hump is a fatty deposit that develops at the back of the neck and upper back. Some patients taking GLP-1 medications experience redistribution of fat in their body, and in certain cases this can result in more noticeable fat accumulation in this area as they lose weight overall. #### If I am losing weight on a GLP-1 medication, why would I develop a buffalo hump? During significant weight loss, your body redistributes fat from different areas at different rates. Some patients experience more pronounced fat deposits in the upper back and neck region even while losing weight in other areas, which is related to how individual bodies naturally store and mobilize fat. #### Is a buffalo hump a permanent side effect of GLP-1 therapy? The permanence of a buffalo hump depends on individual factors and whether the medication is continued. Some patients may see improvement in this area over time, while others may require additional interventions to address the concern. #### How common is buffalo hump formation among GLP-1 users? Clinical reports indicate a growing number of patients experiencing this concern, which is why medical professionals are now providing specific guidance on recognizing and addressing it. However, not all patients taking GLP-1 medications will develop this issue. #### Can I prevent a buffalo hump while taking GLP-1 medications? Maintaining regular physical activity, particularly exercises targeting the neck and upper back, may help with overall fat distribution. Discussing prevention strategies with your physician during treatment can help you understand your individual risk factors. #### What should I do if I notice a buffalo hump developing during GLP-1 treatment? Report this change to your physician promptly so they can evaluate the extent of the deposit and discuss available options with you. Early intervention and professional guidance are important for managing this concern effectively. #### Are there treatments available for buffalo hump that developed from GLP-1 use? Yes, there are medical and cosmetic treatment options available depending on the severity and your preferences. Your physician can discuss these options with you and refer you to appropriate specialists if needed. #### Does stopping my GLP-1 medication eliminate a buffalo hump? Stopping the medication does not guarantee the buffalo hump will disappear on its own. Treatment or additional interventions may be necessary to address the fatty deposit after it has formed. #### Is a buffalo hump a sign that GLP-1 therapy is not working properly? A buffalo hump is not an indication that your medication is failing to work for weight loss. It is a separate concern related to how your individual body redistributes fat during the weight loss process. #### Should I be concerned about a buffalo hump if I have not noticed one yet? You should remain aware of changes in your body while taking GLP-1 medications and discuss any noticeable changes with your physician. Regular check-ins with your doctor allow for early detection and management of any concerns that may arise. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Ozempic Face: GLP-1 Facial Aging & Body Composition](https://cedclinic.com/glp-1-facial-volume-loss-ozempic-face-aging/) Explore how GLP-1 medications affect facial aging and overall body composition, providing insights into aesthetic changes during treatment. [Read More](https://cedclinic.com/glp-1-facial-volume-loss-ozempic-face-aging/) [GLP-1 Receptor Agonist Clinical Evidence for Weight Management](https://cedclinic.com/glp-1-receptor-agonist-clinical-evidence-for-weight-management/) Review clinical evidence supporting the efficacy and safety of GLP-1 receptor agonists in [weight management](https://cedclinic.com/cannabis-metabolism-weight-management-science/) and [metabolic health](https://cedclinic.com/cannabis-compounds-reverse-fatty-liver-disease/). [Learn More](https://cedclinic.com/glp-1-receptor-agonist-clinical-evidence-for-weight-management/) [GLP-1 Weight Loss: Muscle Loss and Body Composition Effects](https://cedclinic.com/rapid-weight-loss-effects-glp-1-body-composition/) Understand the impact of GLP-1 weight loss drugs on muscle mass and body composition, including potential [side effects](https://cedclinic.com/cannabis-intoxication-memory-disruption/) and management tips. [Explore Details](https://cedclinic.com/rapid-weight-loss-effects-glp-1-body-composition/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).